For licensed clinicians
Peptide therapeutics, evidence-graded.
Per-peptide cards with evidence tier, regulatory status, contraindications, study exposure, monitoring guidance, and citations linked to PubMed, ClinicalTrials.gov, and FDA documents. Sourced from the primary literature, not the marketing layer.
- Compounds indexed
- 90
- FDA-approved
- 32
- Cited studies
- 1150
- Updated
- 2026-04-29
What's in a peptide card
Every reference card surfaces the same structured fields, in the same order, so you can scan a peptide in under a minute.
Evidence tier
1 (FDA-approved) through 5 (preclinical only). Tier reflects volume and phase of human research, separate from regulatory status.
Regulatory matrix
FDA approval status, 503A/503B compounding classification, anti-doping status, and current PCAC review state.
Contraindications & cautions
Population cautions, general safety risks, regulatory and product-quality risks — split into separate sections.
Study exposure
Dosing context drawn directly from cited trials and labels. No recommendations.
Monitoring & interactions
Biomarkers and clinical signals that should be tracked when this molecule is in use.
Source links
PubMed, ClinicalTrials.gov, DOI, and FDA label URLs on every claim. Verifier checks every link before publish.
Browse by evidence tier
FDA-approved
Tier 1- Abaloparatide (Tymlos)
- Calcitonin Salmon (Miacalcin, Fortical)
- Cetrorelix (Cetrotide)
- Dasiglucagon (Zegalogue)
- Degarelix (Firmagon)
- Dulaglutide (Trulicity)
FDA-approved drug.
Substantial human evidence
Tier 2Substantial human evidence.
Preclinical / limited human
Tier 4Limited human evidence; signal requires confirmation.
Methodology
Each card is built from a deterministic pipeline that harvests primary sources, runs a verifier pass on every URL and identifier, and applies quality gates before publish.
- 1Primary-source-first discovery: PubMed E-utils, ClinicalTrials.gov v2, OpenFDA, Crossref, OpenAlex, Retraction Watch.
- 2Claims-driven synthesis with explicit source IDs on every claim. No claim ships without a source.
- 3Operational curation pass for chemical identity, dosing context, contraindications, and safety-split fields.
- 4Verifier resolves every URL, PMID, DOI, and NCT ID and checks Retraction Watch before publish.
- 5No dosing recommendations. Study exposure context is presented as cited research, not prescribing guidance.
What this is, and isn't
PeptideReference is a literature reference. It is not medical advice, not a prescribing tool, and not an endorsement of any compounded product. Decisions about whether to use a peptide therapeutic — and which product, formulation, source, dose, and monitoring plan — belong to a licensed clinician evaluating an individual patient.